Search results
Results from the WOW.Com Content Network
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody -based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle ), is the industry leader in antibody-drug conjugates or ADCs ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Seattle Genetics, a cancer-focussed drug developer, will receive an upfront payment of $600 million under the agreement, while Merck will invest the $1 billion to buy 5 million shares of Seattle ...
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us
This was a pivotal year for Seattle Genetics (NAS: SGEN) ; a biotech getting its first drug approved is always a pivotal event, even when it's widely anticipated. Expect more of the same in 2012.
Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies. In May 2014, Alder went public. [1] In early 2018, the company made a public stock offering, aiming to raise US$250 million. [2]